Keros Therapeutics Inc expected to post a loss of $1.34 a share - Earnings Preview

Keros Therapeutics

31/07/2023 14:14

* Keros Therapeutics Inc  KROS.OQ   KROS.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 2
(estimated). 
    * The Lexington Massachusetts-based  company is expected to
report
revenue of $185.71 thousand, according to the mean estimate from
7 analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Keros Therapeutics
Inc is
for a loss of $1.34 per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Keros
Therapeutics Inc is $93​, above​ its last closing price
of $41.97. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -1.13       -1.12      -1.26     Missed  -12.2
 Dec. 31 2023  -1.08       -1.10      -1.09     Beat    0.7
 Sep. 30 2022  -1.23       -1.23      -0.92     Beat    25.3​
 Jun. 30 2022  -1.05       -1.06      -1.13     Missed  -6.8
 ​​Mar.        -0.86       -0.86      -1.01     Missed  -17.1
 31 2022                                                
 Dec. 31 2021  -0.97       -0.92      -0.30     Beat    67.3​
 Sep. 30 2021  -0.72       -0.72      -0.87     Missed  -20.4
 Jun. 30 2021  -0.69       -0.65      -0.67     Missed  -2.3
 This summary was machine generated July 31 at 13:14 GMT.  All
figures in US dollars  unless otherwise stated